Refining the American guidelines for prevention of cardiovascular disease (3)

The Lancet

Volumn 383, Issue 9917, 2014, Pages 598-599

  McCormack, James ^a   Banh, Hoan Linh ^b   Allan, G Micheal ^b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COMPARATIVE STUDY; DECISION MAKING; DIABETES MELLITUS; DISEASE CLASSIFICATION; HUMAN; LETTER; PRIORITY JOURNAL; RISK FACTOR; NOTE; PRACTICE GUIDELINE; PRIMARY PREVENTION;

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

CARDIOVASCULAR DISEASES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PRACTICE GUIDELINES AS TOPIC; PRIMARY PREVENTION;

EID: 84893839515     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(14)60214-2     Document Type: Letter

References (3)

1. Ridker PM, Cook NR Statins: new American guidelines for prevention of cardiovascular disease. Lancet 2013; 382: 1762-65.
2. Goff DC, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013; published online Nov 13. DOI:10.1016/j.jacc.2013.11.005.
3. Allan GM, Nouri F, Korownyk C., Kolber MR, Vandermeer B, McCormack J. Agreement among Cardiovascular Risk Calculators. Circulation 2013; 127: 1948-56.